354 related articles for article (PubMed ID: 10725993)
1. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
Kottke-Marchant K; Powers JB; Brooks L; Kundu S; Christie DJ
Clin Appl Thromb Hemost; 1999 Apr; 5(2):122-30. PubMed ID: 10725993
[TBL] [Abstract][Full Text] [Related]
2. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation.
Van der Planken MG; Claeys MJ; Vertessen FJ; Dilling D; Bosmans JM; Berneman ZN; Michiels JJ; Vrints C
Thromb Res; 2003; 111(3):159-64. PubMed ID: 14678814
[TBL] [Abstract][Full Text] [Related]
3. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
4. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention.
Claeys MJ; Van Der Planken MG; Michiels JJ; Vertessen F; Dilling D; Bosmans JM; Vrints CJ
Blood Coagul Fibrinolysis; 2002 Jun; 13(4):283-8. PubMed ID: 12032392
[TBL] [Abstract][Full Text] [Related]
6. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
Madan M; Berkowitz SD; Christie DJ; Jennings LK; Smit AC; Sigmon KN; Glazer S; Tcheng JE
Am Heart J; 2001 Feb; 141(2):226-33. PubMed ID: 11174336
[TBL] [Abstract][Full Text] [Related]
7. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.
Madan M; Berkowitz SD; Christie DJ; Smit AC; Sigmon KN; Tcheng JE
Am Heart J; 2002 Jul; 144(1):151-8. PubMed ID: 12094202
[TBL] [Abstract][Full Text] [Related]
8. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
[TBL] [Abstract][Full Text] [Related]
9. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
[TBL] [Abstract][Full Text] [Related]
11. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents.
Hézard N; Metz D; Nazeyrollas P; Droulle C; Elaerts J; Potron G; Nguyen P
Thromb Haemost; 2000 Apr; 83(4):540-4. PubMed ID: 10780313
[TBL] [Abstract][Full Text] [Related]
12. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Furman MI; Krueger LA; Linden MD; Fox ML; Ball SP; Barnard MR; Frelinger AL; Michelson AD
J Thromb Haemost; 2005 Feb; 3(2):312-20. PubMed ID: 15670038
[TBL] [Abstract][Full Text] [Related]
13. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
[TBL] [Abstract][Full Text] [Related]
14. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
[TBL] [Abstract][Full Text] [Related]
15. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?
Hézard N; Metz D; Nazeyrollas P; Droullé C; Potron G; Nguyen P
Thromb Res; 2002 Oct; 108(1):43-7. PubMed ID: 12586131
[TBL] [Abstract][Full Text] [Related]
16. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
[TBL] [Abstract][Full Text] [Related]
17. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
18. Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.
Graff J; Andries D; Elsner M; Westrup D; Bassus S; Franz N; Klinkhardt U; Harder S
Br J Clin Pharmacol; 2001 Jun; 51(6):577-82. PubMed ID: 11422017
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.
Graff J; Harder S
Semin Thromb Hemost; 2005; 31(4):482-5. PubMed ID: 16149028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
